Latest Insider Transactions at Eledon Pharmaceuticals, Inc. (ELDN)
This section provides a real-time view of insider transactions for Eledon Pharmaceuticals, Inc. (ELDN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Eledon Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Eledon Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2024
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,927,937
+24.25%
|
-
|
|
May 05
2023
|
Bvf Partners L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,978,932
+33.36%
|
-
|
|
Nov 23
2022
|
Steven Perrin President |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$2,000
$2.6 P/Share
|
|
Dec 20
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+18.18%
|
$8,000
$4.48 P/Share
|
|
Aug 17
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+36.36%
|
$24,000
$6.21 P/Share
|
|
Jun 11
2021
|
Paul Sean Little Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.87 P/Share
|
|
Jun 09
2021
|
David Alexandre C Gros Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$24,000
$8.01 P/Share
|
|
Dec 22
2020
|
Bvf Partners L P > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,289,628
+28.66%
|
-
|
|
Dec 02
2020
|
Orbi Med Israel Gp Ltd. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
103,200
-58.35%
|
$2,167,200
$21.6 P/Share
|
|
Oct 30
2020
|
Logos Global Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
92,040
+6.21%
|
$2,301,000
$25.52 P/Share
|
|
Oct 30
2020
|
Logos Global Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,969
-3.24%
|
$337,194
$26.83 P/Share
|
|
Jul 15
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,566
-0.08%
|
$49,924
$14.26 P/Share
|
|
Jul 14
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
27,861
-0.62%
|
$390,054
$14.41 P/Share
|
|
Jul 13
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
20,611
-0.45%
|
$288,554
$14.2 P/Share
|
|
Jun 16
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,120
-0.02%
|
$15,680
$14.27 P/Share
|
|
Jun 12
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,919
-0.13%
|
$82,866
$14.2 P/Share
|
|
Jun 11
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
27,875
-0.61%
|
$390,250
$14.2 P/Share
|
|
Mar 19
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
46,141
-0.99%
|
$645,974
$14.5 P/Share
|
|
Mar 18
2015
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000
-0.06%
|
$42,000
$14.5 P/Share
|
|
Sep 22
2014
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
325,000
+6.54%
|
$4,875,000
$15.0 P/Share
|
|
Sep 22
2014
|
Novartis Bioventures LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,319,328
+50.0%
|
-
|
|
Jun 15
2014
|
Novartis Bioventures LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
14,777
-0.32%
|
$206,878
$14.2 P/Share
|